Advertisement

The Genetics of Lithium Metabolism in Major Affective Disorders

  • Julien Mendlewicz

Abstract

Various kinetic processes are involved in the fate of a drug from its absorption to its binding to plasma proteins or to various tissues, its biotransformation and interaction with receptor sites, and finally to its excretion. These five major processes take place simultaneously, and genetically transmitted variations can occur through DNA mutations inducing structural alterations in the specific proteins directly involved in these five processes. In a given person, more than one pharmacologically significant mutation can arise and such mutations may not be so rare, as illustrated by phenomena responsible for genetic polymorphisms such as the ABO or the HLA, the pseudocholinesterase and the INH-acetyltransferase polymorphisms. The unimodal gaussian curve indicates genetic homogeneity or polygenic control, while the bimodal (mendelian autosomal dominant trait) or polymodal curve (autosomal recessive) are suggestive of a mechanism controlled by genes at a single locus.

Keywords

Twin Pair Twin Study Bipolar Patient Bipolar Illness Affective Illness 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Ananth, J., Engelsmann, F., Kiriarkos, R. and Kolivakis, T 1979, Prediction of lithium response. Acta Psych. Scand. 60:279–286.CrossRefGoogle Scholar
  2. Bert, J., Saier, J., Dufour, H., Scotto, J.C., Julien, R. and Sutter, J.M., 1977, Modification du sommeil provoquée par le lithium en administration aiguë et en administration chronique. Electroenceph. and Clinical Neurophys. 43: 745–748.CrossRefGoogle Scholar
  3. Carroll, B.J., 1979, Prediction of treatment outcome with lithium. Arch. Gen. Psychiatry. 36:870–878.PubMedCrossRefGoogle Scholar
  4. Cazullo, C.L., and Smeraldi, E. HLA system in psychiatry and psychopharmacology. Progress in Neuropsycho-pharmacology. In press.Google Scholar
  5. Dorus, E, Pandey, G.N. and Davis, J.M., 1975, Genetic determinants of lithium ion distribution. An in vivo monozygotic-dizygotic twin study. Arch. Gen. Psych. 32:1097–1100.CrossRefGoogle Scholar
  6. Dorus, E., Pandey, G.N., Shaughnessy, R., Gaviria, M., Val, E., Ericksen, S. and Davis, J.M., 1979, Lithium transport across red cell membrane: a cell membrane abnormality in manic-depressive illness. Science 205:932–934.PubMedCrossRefGoogle Scholar
  7. Frazer, A., Mendels, J., and Brunswick, D., 1978, Erythrocyte concentrations of the lithium ion: clinical correlates and mechanisms of action. Am. J. Psychiatry 135:1065–1069.PubMedGoogle Scholar
  8. Greil, W., Becker, B.F., and Duhm, J., 1979, “On the relevance of the red blood cell/plasma lithium ratio”, in Cooper, T.B., Gershon, S., Kline, N.S.(eds), Lithium Controversies and Unresolved Issues. Amsterdam: Excerpta Medica.Google Scholar
  9. Kupfer, D.J., Dickar, D., Himmelhoch, J.M., and Detre, T.P., 1975, Are there two types of unipolar depression? Arch. Gen. Psychiatry 32:866–871.PubMedCrossRefGoogle Scholar
  10. Mendels, J., and Frazer, A., 1973, Intracellular lithium concentration and clinical response: Towards a membrane theory of depression. J. Psych. Res. 10: 9–18.CrossRefGoogle Scholar
  11. Mendels, J., and Frazer, A.,, and Baron, J., 1976, Intra-erythrocyte lithium ion concentration and long-term maintenance treatment. Lancet, i:966.CrossRefGoogle Scholar
  12. Mendlewicz, J., Fieve, R.R., and Stallone, F., 1973, Relationship between the effectiveness of lithium therapy and family history. Am. J. Psychiatry 130: 1011–1013.PubMedGoogle Scholar
  13. Mendlewicz, J., Verbanck, P., Linkowski, P. and Wilmotte, J. 1978, Lithium accumulation in erythrocytes of manic- depressive patients:An in vivo twin study. Brit. J. Psychiatry 133:433–444.CrossRefGoogle Scholar
  14. Mendlewicz, J., and Youdim, M.B.H., 1978, Anti-depressant potentiation of 5-hydroxytryptophan by L-Deprenil, an MAO “type B” inhibitor. J. of Neural Transmission 43:279–286.CrossRefGoogle Scholar
  15. Mendlewicz, J., 1979, “Prediction of treatment outcome: family and twin studies in lithium prophylaxis and the question of lithium red blood cell/plasma ratios” in Lithium: Controversies and Unresolved Issues, Cooper, T.B., Gershon, S., Kline, N.S.(eds). Amsterdam: Excerpta Medica.Google Scholar
  16. Mistra, P.C., and Burns, B.H., 1977, Lithium non responders in a lithium clinic. Acta Psychiat. Scand. 55:32–40.CrossRefGoogle Scholar
  17. Perris, C., Stransman, E., and Wahlby, L., 1978, HLA antigens and the response to prophylactic lithium. 11th C.I.N.P Congress, Vienna:9–14 In press.Google Scholar
  18. Prien, R.F., Caffey, E.H., and Klett, C.J., 1974, Factors associated with treatment success in lithium carbonate prophylaxis. Arch. Gen. Psychiatry 31:189–192.PubMedCrossRefGoogle Scholar
  19. Schless, A.P., Frazer, A., and Mendels, J., 1975, Genetic determination of lithium ion metabolism:II. An in vivo study of lithium ion distribution across erythrocyte membranes. Arch. Gen. Psychiatry 32:337–390.PubMedCrossRefGoogle Scholar
  20. Stallone, F., Shelley, E., Mendlewicz, J., 1973, The use of lithium in affective disorders:III. A double blind study of prophylaxis in bipolar illness. Am. J. Psychiat. 130:1006–1010.PubMedGoogle Scholar
  21. Taylor, M. A., and Abrams, R., 1975, Acute mania. Arch. Gen. Psychiatry 32:863–865.PubMedCrossRefGoogle Scholar
  22. Zvolsky, P., Vinarova, E., Dostal, T., 1974, Family history of manic-depressive and endogenous depressive patients and clinical effect of treatment with lithium. Act. Nerv. Sup. (Praha) 16:194–195.Google Scholar

Copyright information

© Springer Science+Business Media New York 1985

Authors and Affiliations

  • Julien Mendlewicz
    • 1
  1. 1.Department of PsychiatryErasme Hospital University Clinic of Brussels Free University of BrusselsBrusselsBelgium

Personalised recommendations